Achievement of low-density lipoprotein cholesterol goals: New strategies to address new guidelines

Cardiology Clinics

Volumn 21, Issue 3, 2003, Pages 363-375

  Illingworth, D Roger ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL DISEASE; CHOLESTEROL METABOLISM; CLINICAL PRACTICE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MORBIDITY; MORTALITY; MYOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 0242385603     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(03)00078-X     Document Type: Review

References (99)

1. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial function and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-7.
2. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2000.
3. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000;102:3137-47.
4. Levine GN, Keaney Jr. JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998;9:471-4.
6. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of CHD. The Framingham Study. Ann Intern Med 1971;74:1-12.
7. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from CHD continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-28.
8. Verschuren WMM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long-term CHD mortality in different cultures. Twenty-five year follow-up of the seven countries study. JAMA 1995;274:131-6.
9. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995;332:1491-8.
10. Feely J. The therapeutic gap-compliance with medication and guidelines. Atherosclerosis 1999;147(Suppl 1):S31-7.
11. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98:851-5.
12. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-7.
13. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10.
14. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161:53-8.
15. Pederson TR, Olsson AG, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major CHD events in the Scandinavian simvastatin survival study (4S). Circulation 1998; 97:1453-60.
16. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446-52.
17. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. prevention of cardiovascular events and death with pravastatin in patients with CHD and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
18. The Expert Panel. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
19. Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
20. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1333-445.
21. Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.
22. Ernst ND, Sempos CT, Briefel RR, Clark MB. Consistency between US dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. Am J Clin Nutr 1997; 66(Suppl):965S-72S.
23. Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The dietary alternatives study. JAMA 1997;278:1509-15.
24. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000;108:496-9.
25. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving national cholesterol education program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc 1999;74:466-73.
26. Poulter NR. Medical education: communicating best practice. Atherosclerosis 1999;143(Suppl 1): S13-16.
27. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-7.
28. McBride P, Schrott HG, Plane MG, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-44.
29. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
30. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
31. US Department of Health and Human Services. Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Vital and health statistics, plan and operation of the third national health and nutrition examination survey, 1988-1994. DHHS publication no. (PHS) 94-1308, series 1, No. 32 4-0485.
32. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
33. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-72.
34. Lai LL, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J 2000;93:283-6.
35. Heudebert GR, Van Ruiswyk J, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity. Arch Intern Med 1993;153:1828-37.
36. Roberts WC. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 1996;78:377-8.
37. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
38. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of CHD with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
40. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
41. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
42. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
43. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6.
44. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
45. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-9.
46. Goldbourt U, Holtzman E, Neufeld HN. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. BMJ 1985;290:1239-43.
47. Witztum JL. Drugs used in the treatment of hyperdyslipidemias. In: Hardman JG, Limbird LE, Molinoff PB, et al, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 9th edition. New York: McGraw-Hill International Book Co; 1996 [chapter 36].
48. Russell DW. Cholesterol biosynthesis and man. Cardiovasc Drugs Ther 1992;6:103-10.
49. Illingworth DR. Management of hypercholesterolemia. Med Clin N Am 2000;84:23-42.
50. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
51. Safeer RS, Lacivita CL. Choosing drug therapy for patients with hyperlipidemia. Am Fam Physician 2000;61:3371-82.
52. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999;65:1329-37.
53. Blum CB. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73(Suppl):3D-11D.
54. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
55. Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997;53:828-47.
56. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998;55:2253-67.
57. Tikkanen MJ. Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996;7:385-8.
58. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
59. Ballantyne CM, Corsini A, Davidson MH, et al. Risk from myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64.
60. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3-11.
61. Walldius G, Wahlberg G. Nicotinic acid and its derivatives. In: Betteridge DJ, Illingworth DR, Shepherd J, editors. Lipoproteins in health and disease. London: Arnold Publishers; 1999. p. 1181-97.
62. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994;154:1586-95.
63. Rader JI, Calvert RJ, Hathcock JM. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81.
64. Grundy SM, Vega GL, Bilheimer DW. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 1985;103:339-43.
65. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
66. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-9.
67. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
68. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
69. Farmer JA, Gotto AM. Anithyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf 1994;11:301-9.
70. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900.
71. Colesevelam. (Welchol) for hypercholesterolemia. Med Lett Drugs Ther 2000;42:102-4.
72. Miettinen TA, Gylling H. Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipidol 1999;10:9-14.
73. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant sterol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr 2000;130:767-76.
74. Cholesterol-lowering margarines. Med Lett Drug Ther 1999;41:56-8.
75. van Heek M, Farley C, Compton D, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54.
76. van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-63.
77. van Heek M, Farley C, Compton D, et al. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically [abstract]. Atherosclerosis 2000;151:155.
78. Zhu Y, Statkevich P, Kosoglou T, et al. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor [abstract]. AAPS 1999;1(Suppl):S24.
79. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption [abstract], Eur Heart J 2000;21(Suppl):636,
80. van Heek M, Farley C, Compton D, Hoos L, Davis H, The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function [abstract]. AAPS 2000;2(Suppl):3476.
81. Knopp RH, Bays H, Manion CV, et al, for the Ezetimibe Study Group. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins [abstract], Atherosclerosis 2001;2(Suppl):90. Abstract P175.
82. Davis HR, van Heek M, Watkins RW, et al. The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors [abstract]. In: Program and Abstracts of the XII International Symposium on Drugs Affecting Lipid Metabolism (DALM); Houston, TX; November 1995:62.
83. Catapano AL. Ezetimibe: a selective inhibitor of cholesterol absorption, Eur Heart J 2001;3(Suppl E): E6-10.
84. van Heek M, Austin T, Cook J, Farley C, Tetzloff G, Davis H. The potent cholesterol absorption inhibitor, ezetimibe, ablates hypercholesterolemia and hypertriglyceridemia in a model of combined hyperlipidemia [abstract]. Atherosclerosis 2000;151:132.
85. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001;415:79-84.
86. Davis Jr. HR, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism 2001;50:1234-41.
87. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo [abstract]. Clin Pharmacol Ther 2000;67:152.
88. Bauer KS, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin [abstract]. Clin Pharmacol Ther 2001;69:15.
89. Keung ACF, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives [abstract]. Clin Pharmacol Ther 2001;68:55.
90. Statkevich P, Reyderman L, Kosoglou T, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide [abstract]. Clin Pharmacol Ther 2001;68:67.
91. Kosoglou T, Statkevich P, Bauer KS, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin [abstract]. AAPS Supplement 2001;3(Suppl 3).
92. Knopp RH, Gitter H, Truitt T, et al, for the Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
93. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.
94. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
95. Davidson MH, McGarry T, Bettis R, et al, for the Ezetimibe Study Group. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
96. Ballantyne CM, Houri J, Notarbartolo A, et al, for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.
97. Melani L, Mills R, Hassman D, et al, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28.
98. Kerzner B, Corbellí J, Sharp S, et al, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91: 418-24.
99. Kosoglou T, Guillaume M, Sun S, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]. Atherosclerosis 2001;2(Suppl):38.